Kandidiasis Vaginalis

01Pathophysiology

Candida species are normal commensals of the vaginal flora in approximately 20-30% of women. The organism exists in a balanced ecosystem alongside Lactobacillus species, which serve as the primary defense mechanism. Lactobacilli produce lactic acid and hydrogen peroxide, maintaining the vaginal pH in the acidic range (3.8 to 4.5) and inhibiting overgrowth of potentially pathogenic organisms including Candida.

Disease occurs when this equilibrium is disrupted. Antibiotic use is the most classic trigger tested on exams. Broad-spectrum antibiotics eliminate Lactobacillus populations, removing the competitive inhibition that keeps Candida in check. Without this restraint, the yeast transitions from its commensal yeast form to the pathogenic hyphal form, which penetrates the vaginal epithelium and triggers an inflammatory response. This is why pruritus, erythema, and edema dominate the clinical picture.

Estrogen plays a central role in susceptibility. Elevated estrogen levels (from pregnancy, combined oral contraceptives, or hormone replacement therapy) increase glycogen deposition in the vaginal epithelium. Glycogen is broken down into glucose, which serves as a carbon source for Candida proliferation. This explains why vulvovaginal candidiasis is rare before menarche and after menopause, and why it peaks during the reproductive years and pregnancy.

Diabetes mellitus promotes candidiasis through a related mechanism. Elevated blood glucose levels lead to increased glucose concentrations in vaginal secretions, directly fueling Candida growth. Poorly controlled diabetes also impairs neutrophil function, further weakening local immune defenses.

Cell-mediated immunity (T-helper type 1 response) is the dominant host defense against mucosal Candida infections. This is why patients with HIV/AIDS or those on immunosuppressive therapy are prone to recurrent and severe candidal infections. Notably, the vaginal pH remains normal (< 4.5) in candidiasis because the Lactobacillus population, while relatively suppressed, is not eliminated in the same way it is in bacterial vaginosis.

02Classification and Clinical Manifestation

The distinction between uncomplicated and complicated disease is the single most important classification concept tested on exams, because it determines the treatment approach.

Clinical Manifestation by Severity

A critical clinical point: the discharge in candidiasis is characteristically thick, white, curd-like, and odorless. The absence of odor is a strong discriminator from bacterial vaginosis (which has a "fishy" amine odor). Dysuria, when present, is external (burning when urine contacts the inflamed vulvar skin), not internal (which would point toward a urinary tract infection).

03Diagnostic Workup

Vaginal pH is the first branch point in the diagnostic algorithm. A pH below 4.5 immediately narrows the differential to candidiasis. Both bacterial vaginosis and trichomoniasis produce an elevated pH (> 4.5), so a normal pH effectively rules those conditions out. This is a quick, inexpensive bedside test and is heavily tested.

The KOH preparation is the best initial diagnostic test. Adding 10% potassium hydroxide to a vaginal discharge sample lyses epithelial cells and bacteria, making fungal elements easier to visualize. The hallmark finding is pseudohyphae (elongated chains of yeast cells with constriction points) or budding yeast. However, the sensitivity of KOH prep is only around 50-70%, meaning a negative result does not exclude the diagnosis.

The whiff test is performed simultaneously by smelling the KOH-treated slide. A positive whiff test (release of volatile amines producing a "fishy" odor) indicates bacterial vaginosis, not candidiasis. In candidiasis, the whiff test is negative.

Vaginal culture (typically on Sabouraud agar or chromogenic media) is the most accurate test and is reserved for situations where clinical suspicion is high but the KOH prep is negative, or when non-albicans species are suspected (treatment-resistant or recurrent infections). Culture also allows speciation, which guides therapy. This is particularly relevant when dealing with C. glabrata, which is often resistant to fluconazole.

A practical exam pearl: you do not need a culture for a straightforward first episode of candidiasis with classic symptoms and a positive KOH prep. Culture becomes necessary in recurrent disease, treatment failure, or when the presentation is atypical.

04Management and Treatment

Uncomplicated vulvovaginal candidiasis is treated with a single oral dose of fluconazole 150 mg. This is the first-line regimen due to its convenience, high efficacy (> 90% cure rate for C. albicans), and patient preference. Topical azoles (clotrimazole, miconazole, terconazole) are equally effective and serve as alternatives, particularly when oral therapy is not desired or is contraindicated. There is no proven benefit of treating the male sexual partner in uncomplicated cases.

For severe disease (marked by extensive vulvar erythema, edema, excoriation, or fissure formation), a single dose is insufficient. The recommended approach is fluconazole 150 mg on day 1 and day 4, with some guidelines adding a third dose on day 7. The rationale is that severe inflammation requires a longer duration of antifungal exposure to achieve clinical and mycological cure.

Recurrent vulvovaginal candidiasis is defined as 4 or more symptomatic episodes in a 12-month period. This is a commonly tested threshold. Management involves two phases. The induction phase uses fluconazole 150 mg on days 1, 4, and 7 to achieve initial clearance. This is followed by a maintenance phase of fluconazole 150 mg once weekly for 6 months. After discontinuation, approximately 50% of patients will relapse, and some may need a longer or indefinite suppressive course. Culture and speciation should be performed to exclude non-albicans species before committing to a long-term azole regimen.

Pregnancy is a critical contraindication to oral fluconazole. Fluconazole, particularly at higher or repeated doses, is classified as teratogenic and has been associated with craniofacial and cardiac abnormalities. The only acceptable treatment in pregnancy is topical azoles (intravaginal clotrimazole or miconazole) for a full 7-day course. This is one of the most tested contraindications in this topic.

For infections caused by non-albicans species, particularly C. glabrata, standard fluconazole therapy often fails because these organisms carry intrinsic or acquired azole resistance. The recommended alternative is intravaginal boric acid 600 mg capsules daily for 14 days. If boric acid is unavailable or fails, intravaginal nystatin or flucytosine cream are second-line options. Importantly, boric acid is toxic if ingested orally and must only be used intravaginally.

05Differential Diagnosis and Distractors

The most commonly tested distractor is bacterial vaginosis. The exam writers rely on three branch points to distinguish them: discharge character (thick vs. thin), odor (absent vs. fishy), and pH (normal vs. elevated). Memorize these three parameters and you can reliably differentiate the two conditions.

06Traps and High-Yield Pearls

The most common trap in exam questions on vulvovaginal candidiasis involves pH. Many students associate all forms of vaginitis with an elevated pH, but candidiasis is the notable exception. A vignette describing pruritus, vaginal discharge, and a pH of 4.0 should immediately point toward candidiasis. If the vignette gives a pH above 4.5, you need to pivot to bacterial vaginosis or trichomoniasis regardless of how "yeast-like" the discharge sounds.

The second major trap is fluconazole in pregnancy. A vignette will describe a pregnant woman with classic candidiasis and offer fluconazole as one of the answer choices. This is always wrong. The correct answer is a topical azole for 7 days. This tests whether you know the teratogenicity concern with oral azoles.

A third commonly tested angle involves treatment failure. When a patient returns with persistent symptoms after appropriate fluconazole therapy, the next step is to obtain a vaginal culture with speciation. The exam is testing whether you recognize that non-albicans species (particularly C. glabrata) are inherently resistant to fluconazole, and that boric acid is the appropriate alternative.

Finally, be careful with the KOH prep. A negative KOH prep does not rule out candidiasis. If clinical suspicion remains high (classic symptoms, normal pH, negative whiff test), the next step is culture, not reassurance. The core competency being tested across all these scenarios is pattern recognition of the classic presentation (pruritus, cottage cheese discharge, normal pH, pseudohyphae) combined with the ability to navigate contraindications and treatment-resistant cases.